PA
DNLI icon

Profund Advisors’s Denali Therapeutics DNLI Stock Holding History

Profund Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.28M Sell
49,899
-18,328
-27% -$377K 0.04% 293
2026
Q1 		$1.31M Sell
68,227
-3,407
-5% -$67.8K 0.05% 275
2025
Q4 		$1.18M Buy
71,634
+31,478
+78% +$531K 0.04% 312
2025
Q3 		$583K Buy
40,156
+13,433
+50% +$193K 0.02% 464
2025
Q2 		$374K Sell
26,723
-1,146
-4% -$16.1K 0.01% 576
2025
Q1 		$379K Sell
27,869
-866
-3% -$16.6K 0.02% 572
2024
Q4 		$586K Buy
28,735
+3,877
+16% +$99.3K 0.02% 434
2024
Q3 		$724K Sell
24,858
-4,515
-15% -$112K 0.03% 402
2024
Q2 		$682K Sell
29,373
-39,101
-57% -$751K 0.03% 403
2024
Q1 		$1.41M Buy
68,474
+14,799
+28% +$278K 0.05% 254
2023
Q4 		$1.15M Buy
53,675
+13,521
+34% +$268K 0.05% 300
2023
Q3 		$828K Sell
40,154
-6,321
-14% -$160K 0.05% 329
2023
Q2 		$1.37M Sell
46,475
-2,352
-5% -$66.1K 0.07% 236
2023
Q1 		$1.12M Buy
48,827
+33,960
+228% +$935K 0.07% 274
2022
Q4 		$413K Buy
14,867
+1,905
+15% +$56.7K 0.03% 482
2022
Q3 		$398K Buy
12,962
+186
+1% +$6.05K 0.03% 458
2022
Q2 		$376K Sell
12,776
-1,478
-10% -$38.7K 0.02% 523
2022
Q1 		$459K Sell
14,254
-1,586
-10% -$54.6K 0.02% 623
2021
Q4 		$706K Sell
15,840
-1,813
-10% -$85.9K 0.02% 439
2021
Q3 		$891K Buy
17,653
+14,982
+561% +$844K 0.03% 396
2021
Q2 		$210K Buy
+2,671
New +$165K 0.01% 1323

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Profund Advisors's DNLI Position: Q2 2026 in Review

Profund Advisors reduced its Denali Therapeutics (DNLI) stake by 27% in Q2 2026, selling an estimated $377K and leaving 49,899 shares worth $1.28M. The position accounts for 0.04% of the portfolio, ranked #293.

Profund Advisors first reported a position in DNLI in Q2 2021 and has held it in 21 quarters since. The position peaked at $1.41M in Q1 2024. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Profund Advisors held 49,899 shares of Denali Therapeutics worth $1.28M as of Q2 2026.
  • Profund Advisors sold 18,328 Denali Therapeutics shares in Q2 2026, an estimated $377K.
  • Denali Therapeutics made up 0.04% of Profund Advisors's portfolio in Q2 2026, its #293 holding.
  • Profund Advisors first reported a position in Denali Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Profund Advisors's Denali Therapeutics position peaked at $1.41M in Q1 2024.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.